- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 29
- States / cities
- Fresno, California • Glendale, California • Irvine, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-Small Cell Lung Cancer - Completely Resectable
- Interventions
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Biological
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Philadelphia, Pennsylvania
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Immunotherapeutic GSK2302032A, different formulations
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 49
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 40 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 15
- States / cities
- Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more